Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Other Accumulated Expenses (2019 - 2025)

Bioadaptives' Other Accumulated Expenses history spans 6 years, with the latest figure at $1023.0 for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses changed 0.2% to $1023.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1023.0, a 0.2% change, with the full-year FY2025 number at $1023.0, changed 0.2% from a year prior.
  • Other Accumulated Expenses hit $1023.0 in Q4 2025 for Bioadaptives, roughly flat from $1018.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for BDPT hit a ceiling of $1023.0 in Q4 2025 and a floor of $1015.0 in Q4 2022.
  • Historically, Other Accumulated Expenses has averaged $1019.4 across 4 years, with a median of $1019.0 in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: rose 0.39% in 2023 and later dropped 0.39% in 2025.
  • Tracing BDPT's Other Accumulated Expenses over 4 years: stood at $1015.0 in 2022, then grew by 0.39% to $1019.0 in 2023, then rose by 0.2% to $1021.0 in 2024, then increased by 0.2% to $1023.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for BDPT at $1023.0 in Q4 2025, $1018.0 in Q2 2025, and $1019.0 in Q1 2025.